Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03789552 · ClinicalTrials.gov registry record · Phase 3
Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina
A Phase 3 study of Chronic Stable Angina Pectoris, sponsored by Tasly Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 765
- Enrollment target
- 1
- Study location
NCT03789552: Recruiting Phase 3 study of Chronic Stable Angina Pectoris, sponsored by Tasly Pharmaceuticals.
NCT03789552 is a Phase 3 study of Chronic Stable Angina Pectoris that is actively recruiting participants, run by Tasly Pharmaceuticals. The registered enrollment target is 765 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03789552, a Phase 3 study of Chronic Stable Angina Pectoris, is actively recruiting participants, sponsored by Tasly Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 765 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a multi-center, double-blind, randomized, placebo-controlled, parallel-group phase 3 clinical study to confirm the safety and efficacy of T89 in patients with stable angina pectoris, with an extended open-label period to evaluate the long-term safety of T89. This study includes three main periods: the first study period is a 3-week single-blind qualifying run-in period to screen eligible stable angina patients by exercise tolerance test (ETT). The second study period is a 8-week double-blind treatment period to evaluate the efficacy and safety of T89 in patients with stable angina by ETT. And, the last study period is a 44-week open-label period to observe long-term use safety of T89.
Primary Outcome
Exercise, a common physiological stress, can elicit cardiovascular abnormalities that are not present at rest, and it can be used to determine the adequacy of cardiac function. Clinical exercise tolerance test (ETT) is an established non-invasive procedure that provides diagnostic and prognostic information for the evaluation of several pathologies, the most common of which is coronary heart disease. Total exercise duration (TED) is the time from starting ETT to terminating ETT, usually presente
Conditions Studied
Interventions
- DRUG T89 capsule
- DRUG Placebo capsule
Study Locations (1)
Florida
- Southwest Florida Research LLC - Naples
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 765 participants |
| Start Date | 2019-08-01 |
| Est. Completion | 2027-03 |
| Phase | Phase 3 |
What NCT03789552 shows while recruiting
NCT03789552 is an interventional study that assigns participants to a tested intervention. The registered 765 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 1 condition, with Chronic Stable Angina Pectoris appearing as the primary indexed condition, and to 2 interventions - of which T89 capsule is the first listed.
NCT03789552 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT03789552 about?
NCT03789552 is a clinical study titled "Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina". This is a multi-center, double-blind, randomized, placebo-controlled, parallel-group phase 3 clinical study to confirm the safety and efficacy of T89 in patients with stable angina pectoris, with an extended open-label period to evaluate the long-term safety of T89. This study includes three main pe...
What is the current status of trial NCT03789552?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 765 participants. The study started on 2019-08-01. Estimated completion is 2027-03.
What conditions does trial NCT03789552 study?
This clinical trial studies the following conditions: Chronic Stable Angina Pectoris.
What interventions are being tested in trial NCT03789552?
The interventions under investigation include: T89 capsule (DRUG), Placebo capsule (DRUG).
Who is sponsoring clinical trial NCT03789552?
This trial is sponsored by Tasly Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03789552 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03789552's enrollment target sits among peer trials
765 446th of 2000 higher than 1,553 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07195591 · 766 participants · Phase 3
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
- NCT04578665 · 764 participants · NA
Human-like Robotic Controllers for Enhanced Motor Learning
- NCT05579366 · 764 participants · Phase 1
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- NCT05119556 · 768 participants · NA
Video Telehealth Pulmonary Rehabilitation to Reduce Hospital Readmission in Chronic Obstructive Pulmonary Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI